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Abstract
Background: Human promoter polymorphisms in the chemokine co-receptor 5 gene (CCR5) have been noted for
association with mother-to-child transmission of HIV (HIV MTCT) as well as reduced receptor expression in vitro, but have
not been clearly associated with CCR5 expression in vivo. Placental expression of CCR5 may be influenced by such
polymorphisms as well as other in vivo regulatory factors.
Methodology/Principal Findings: We evaluated the associations between infant CCR5 polymorphisms, measures of
maternal infection, and placental expression of CCR5 among mother-infant pairs in Blantyre, Malawi. RNA was extracted
from placental tissue and used in multiplex real-time PCR to quantify gene expression. Through linear regression, we
observed that CCR5-2554T (b=20.67, 95% CI=21.23, 20.11) and -2132T (b=20.75, 95% CI=20.131, 20.18) were
significantly associated with reduced placental expression of CCR5. An incremental increase in CCR5 expression was
observed for incremental increases in expression of two heparan sulfate genes involved in viral infection, HS3ST3A1
(b=0.27, 95% CI=0.18, 0.35) and HS3ST3B1 (b=0.11, 95% CI=0.06, 0.18). Among HIV infected mothers, an incremental
increase in maternal HIV viral load was also associated with higher CCR5 expression (b=0.76, 95% CI=0.12, 1.39). Maternal
HIV status had no overall effect (b=0.072, 95% CI=20.57, 20.72). Higher CCR5 expression was observed for mothers with
malaria but was not statistically significant (b=0.37, 95% CI=20.43, 1.18).
Conclusions/Significance: These results provide in vivo evidence for genetic and environmental factors involved in the
regulation of CCR5 expression in the placenta. Our findings also suggest that the measurement of placental expression of
CCR5 alone is not an adequate indicator of the risk of mother-to-child transmission of HIV.
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Introduction
In sub-Saharan Africa, over 1,300,000 pregnant women were
living with HIV in 2007, and more than 300,000 children are
newly infected with HIV each year, primarily through mother-to-
child transmission (HIV MTCT) [1]. HIV MTCT can occur
during pregnancy (intrauterine transmission), during labor and
delivery (intrapartum transmission), or through breastfeeding
(postpartum transmission).
The chemokine (CC motif) receptor 5 (CCR5), a co-receptor of
the CD4 receptor, is used by macrophage-tropic (R5) HIV-1 for
cell entry [2] and is genetically regulated by the CCR5 gene [3]. It
has been demonstrated that HIV infection and progression is
inhibited by competitive ligands (i.e. the chemokine RANTES)
binding with the CCR5 receptor [4,5]. Genetic variants of the
CCR5 gene such as the 32-basepair deletion in the open reading
frame (CCR5 D32) and promoter polymorphisms are also
associated with human susceptibility to infection and/or progres-
sion of HIV-1 [2,6,7,8,9,10,11,12,13]. This is likely explained by
variable receptor expression resulting from mutation [14,15,16].
Upregulation of CCR5 in the placenta has been noted to
increase the risk of HIV MTCT [17]. However, CCR5 expression
may be altered not only by variants in the CCR5 gene but also by
environmental factors such as maternal infection. Variability in
such factors may limit the external validity of in vivo findings. Thus,
one aim of this study was to evaluate the affects of infant CCR5
promoter polymorphisms, maternal HIV infection, maternal HIV
viral load, and maternal malaria, on CCR5 expression in placental
tissue from mother-infant pairs in Malawi.
In cells lacking the CD4 receptor, such as brain microvascular
endothelial cells (BMECs), or primary genital epithelial cells
(PGECs), alternative routes for HIV-1 attachment and cell entry
have been suggested, including the use of heparan sulfate
proteoglycans (HSPGs) [18,19]. HSPGs are one type of proteo-
glycan, which is composed of a core protein (i.e. syndecan) and
one or more covalently attached glycosaminoglycan (GAG) chains.
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9212HSPGs are proteoglycans with heparan sulfate (HS) attached, a
highly sulfated polysaccharide made up of glucosamine and
glucuronic/iduronic acid repeating disaccharide units [20]. The
binding properties and thereby function of HSPGs are deter-
mined by the structure and sequence of the disaccharide units,
consequential of HS biosynthesis. Various HS subtypes are
produced through HS biosynthesis, which involves genetically
regulated biosynthetic enzymes. One example subtype is 3-O-
sulfated HS, synthesized by 3-O-sulfotransferase, which is encoded
by the genes, heparan sulfate (glucosamine) 3-O-sulfotransferase
3A1 (HS3ST3A1) and B1 (HS3ST3A1). The 3-O-sulfated HS
subtype has been shown to play a key role in susceptibility to
herpes simplex virus -1 (HSV-1) infection in vitro [21,22,23] but has
not been evaluated in the context of HIV-1 infection.
Although not specific to HS subtype, it is known that HSPGs
can facilitate internalization of HIV-1 transactivator protein, Tat
[24], which can induce cytokine activity and bind to heparan [25].
Treatment of cells bearing HSPGs with heparinase diminishes
HIV-1 attachment and infectivity for CD4+ HeLa cells and
macrophages [26,27], an effect that was shown to differ between
HIV viruses using CCR5 as a coreceptor compared to the
CXCR4 coreceptor [28]. Furthermore, chemokines such as
RANTES, MIP-1a, and MIP-1ß, bind not only with the CCR5
coreceptor but also with glycossaminoglycans (GAGs) bearing
heparin, heparan sulfate, or chondroitin sulfate A or C [29,30,31].
GAGs can also strongly influence the activity of chemokines
[32,33]. Specifically, chemokines can be stored and released from
T lymphocytes cytolotic granules complexed to GAGs [34], and
binding with GAGs can influence chemokine structure and lead to
aggregation, possibly protecting chemokines from degradation
[35]. One study demonstrated that CCL5 (RANTES)-CCR5
binding-mediated apoptosis was dependent on cell-surface GAG
binding and that the addition of exogenous heparin or chondroitin
sulfate plus GAG digestion protected cells from apoptosis [36].
More recent studies have suggested that GAGs facilitate
chemokine binding with receptors [35,37], perhaps through
electrostatic interactions [38].
It is likely that both CCR5 and HS play a role in HIV MTCT,
possibly through interactions within placental tissue. Because
CCR5 and HS are genetically regulated, evaluation of pertinent
gene expression may provide clues for what takes place at the
protein level. Thus, in addition to an evaluation of CCR5
expression in the placenta, we quantified the expression of two
key HS genes highly expressed in the placenta [39]: HS3ST3A1
and HS3ST3B1, responsible for the synthesis of 3-O-sulfated HS.
HS gene expression was evaluated for association with CCR5
expression as well as with susceptibility to HIV MTCT in Malawi.
The overall aim of this work was to describe how genetic and
environmental factors may regulate CCR5 expression in the
placenta.
Methods
Ethics Statement
This research was approved by the University of North
Carolina Institutional Review Board and the University of Malawi
College of Medicine Research Ethics Committee (COMREC).
Written informed consent was obtained from all study participants
at the time of recruitment. Consent forms were in both English
and Chichewa languages.
Study Population
The participants were a subset of a larger cohort study of
malaria and HIV in pregnancy (MHP), previously described
[40,41]. Fresh placental tissue samples from the MHP cohort were
obtained from consenting study participants at delivery and
immediately frozen at 280 degrees Celsius (uC). Placental tissue
samples from 723 HIV positive mothers and 419 HIV negative
mothers were transported to the University of North Carolina at
Chapel Hill. Of the HIV positive mothers, a total of 411 samples
had data on transmission status of the infant.
There were five transmission groups of interest: 1) HIV negative
mother/negative infant, 2) HIV positive mother/negative infant at
all visits, 3) HIV positive mother/intrauterine transmission to the
infant, 4) HIV positive mother/intrapartum transmission to the
infant, and 5) HIV positive mother/postpartum transmission to
the infant. Power analyses indicated that a sample size of 200
would provide 80% power to detect a difference in r
2 of 0.03
across groups. To obtain a slightly larger sample size of 250, a
sample of 50 individuals was randomly selected from each of the
five transmission categories, where possible. Only 47, 49, and 17
mother-infant pairs were available for intrauterine, intrapartum,
or postpartum transmission events, respectively, giving a total
sample size of N=213.
Gene Expression and Genotyping
RNA was extracted from frozen placental tissue of the 213
mother-infant pairs using RNeasy mini kit (Qiagen, Valencia, CA).
In order to quantify gene expression for each RNA sample,
multiplex real-time PCR was run on 96-well plates using ABI 7700
Sequence Detector (PE Biosystems) according to methods
previously described [42]. A total volume of 30 ml was used,
which included 10 ml of RNA and 20 ml reaction mixture [42].
The cycle conditions were 30 min at 48uC for the RT reaction,
10 min at 94uC, and then 40 temperature cycles (15 sec at 94uC
and 1 min at 60uC). Relative quantification was performed where
each 96-well plate was normalized to an endogenous placental
RNA control sample. Negative control samples (water) were used
to assess the presence of genomic DNA contamination. The
difference in cycle threshold (Ct) value between a control gene,
GAPDH, and target gene (HS3ST3A1, HS3ST3B1,o rCCR5) was
obtained for each sample (DCt). That value was subtracted from
the DCt value of the endogenous control sample (DDCt) and then
transformed to a percent change in gene expression between
GAPDH and the target gene for each sample. Infant genotyping of
CCR2-64I and CCR5 promoter polymorphisms were determined
using a multiplex ligase detection reaction (LDR) based method
with flow cytometric technology, previously described [43,44].
Briefly, the CCR5 promoter region containing the seven promoter
SNPs and the CCR2 open reading frame were PCR-amplified.
The amplicon was probed with an upstream allele specific primer
with a unique 24 nucleotide FlexMAP
TMTAG sequence extension
(LuminexH Corporation, Austin, TX) and a downstream 59
phosphorylated/39 biotinylated conserved sequence primer. After
allele specific hybridization, the primers were ligated, ligation
products were hybridized with fluorescent bead-labeled anti-TAG
probes, and the 39 biotin group was labeled with phycoerythrin
(PE). To determine genotypes, the mean fluorescence intensity of
the allele-specific LDR:bead-labeled anti-TAG hybrid complexes
was read on a BioPlex array reader (Bio-Rad Laboratories,
Hercules, CA) into allele specific channels [43,44].
Statistical Analysis
The percent change in CCR5 expression was log-transformed in
order to approximate a normal distribution. Infant CCR2/CCR5
SNPs were categorized into haplotypes (Table S1), based on
phylogeny as previously described [45]. In order to evaluate the
association between SNP/haplotype and CCR5 expression in the
Regulation of CCR5 Expression
PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9212placenta, linear regression was performed using log-transformed
CCR5 expression as the continuous outcome. Logistic regression was
also employed to evaluate the association between SNP/haplotype
andhighvs.lowCCR5expression,dichotomizedatthemedianvalue.
Duetosmallcellsizesforsomepolymorphisms,SNPsandhaplotypes
were categorized as carriers of the variant/haplotype compared to
non-carriers and analyzed according to a dominant genetic model.
Because the SNPs were not completely independent, exhibiting
variable pairwise linkage disequilibrium (Table S2), Bonferroni
correction was not employed to adjust for multiple comparisons.
The percent change in HS3ST3A1 expression and HS3ST3B1
expression were also log-transformed and individually evaluated
for association with CCR5 expression through linear regression,
using CCR5 expression as the continuous outcome. Measures of
maternal infection including maternal HIV, maternal HIV viral
load (MVL), and maternal malaria were uniquely evaluated for
association with CCR5 expression, also through linear regression.
Finally, gene expression of CCR5, HS3ST3A1, and HS3ST3B1
was investigated for association with HIV MTCT through logistic
regression. HIV MTCT was coded as 1 (transmission occurred) vs.
0 (no transmission). Different transmission time points (IU, IP, and
PP) were evaluated in independent logistic regression models.
Because gene expression did not meet the assumption of linearity
of the logit, it was categorized into tertiles for this model.
Because MVL is known to be a strong predictor of HIV
MTCT, it was evaluated for effect measure modification of the
association between gene expression and HIV MTCT by
calculating the Mantel-Haenszel test of homogeneity of the odds
ratio (OR) across MVL quartiles. It was also evaluated for
confounding by using the percent change in estimate criterion:
|ln(CoRR)|*100.10%, where |ln(CoRR)|=|ln(crude OR–ad-
justed OR)|*100 [46].
Results
Study Population
A total of 212 mother-infant pairs evaluated for gene expression
had previously been genotyped for CCR2/CCR5 polymorphisms
[43]. This included 154 HIV positive mothers, 103 (67%) of which
had infants who became HIV positive by 12 weeks postpartum
and 51 (33%) of which had HIV negative infants. Following
quality control, CCR5 SNP genotypes and placental expression
was available for 196 mother-infant pairs. This included 44 (22%)
HIV negative infants of HIV positive mothers, 98 (50%) HIV
positive infants of HIV positive mothers, and 54 (28%) HIV
negative infants of HIV negative mothers. A total of 160 mother-
infant pairs also had data on HIV maternal viral load.
CCR5 Gene Expression and CCR5 Variants
The overall mean and standard deviation (SD) of the cycle
threshold values were 26.99 (SD=4.00), 27.93 (SD=3.92), 24.56
(2.27), and 24.51 (SD=3.50) for GAPDH, HS3ST3A1, HS3ST3B1,
and CCR5, respectively. The mean and SD of the log %change in
gene expression relative to GAPDH expression was 5.83
(SD=1.39), 4.63 (SD=0.83), and 5.74 (SD=2.02), for
HS3ST3A1, HS3ST3B1, and CCR5, respectively. The CCR5-
2132CRT variant was significantly associated with variable
placental expression of CCR5 (Table 1), where carriers of the T
variant displayed lower placental expression of CCR5 (mean log
%change=5.53, range=21.61, 9.40) compared to non carriers
(mean log %change=5.87, range=1.95, 14.55). The CCR5-2554
GRT variant was also significantly associated with a lower
expression of CCR5 (mean log %change for T allele=5.69,
range=21.61, 9.91; mean log %change for G allele=5.77,
range=1.95, 14.55), although this finding was not statistically
significant in the analysis of high vs. low expression (Table 1). The
minor allele frequency for CCR5-2132T and -2554T was 0.23 and
0.29, respectively. CCR5 SNPs -2459G, -2135T, and -1835T
corresponded to a lower risk of HIV MTCT, but these results were
not statistically significant (Table 1).
The A haplotype, which contains the infant alleles CCR5 -
2132C and -2554G (Table S1), was associated with higher
expression of CCR5 in the placenta (Table 1). A statistically
significant association in the opposite direction (lower expression
of CCR5) was observed for haplotype D (Table 1), which contains
CCR5 -2132T and -2554T. All other alleles were the same across
haplotypes A and D. Associations between CCR5 expression and
other haplotypes were not statistically significant (Table 1).
Gene Expression Interplay in the Placenta
An interesting interplay between placental expression of
HS3ST3A1, HS3ST3B1, and CCR5 was observed in this study.
An incremental increase in placental expression of HS3ST3A1 or
HS3ST3B1 corresponded to an incremental increase in placental
expression of CCR5 (Figure 1). The positive association between
placental expression of HS3ST3A1 or HS3ST3B1and CCR5
expression was statistically significant (Table 2).
CCR5 Expression and Measures of Maternal Infection
Maternal HIV infection was not associated with CCR5
expression in the placenta (b=0.072, 95% CI=20.57, 20.72,
p=0.826, N=194). However, among the HIV infected mothers,
maternal HIV viral load was associated with CCR5 expression,
where an incremental increase in viral load corresponded to an
incremental increase in CCR5 expression (b=0.76, 95%
CI=0.12, 1.39; p=0.020, N=92). Maternal malaria infection
also corresponded to a higher placental expression of CCR5, but
the association was not statistically significant (b=0.37, 95%
CI=20.43, 1.18, p=0.362, N=170).
Gene Expression and Risk of HIV MTCT
A general trend of increasing risk of HIV MTCT with increasing
expression of CCR5 was observed but these findings were not
statistically significant (Medium vs. low tertile OR=1.16, 95%
CI=0.49, 2.73; High vs. low tertile OR=1.26, 95% CI=0.52,
3.03). Log maternal viral load did not modify the association
between HIV MTCT and placental expression of CCR5 (Mantel-
Haenszel OR=0.22, p=0.683). In addition, MVL was not a
confounder in the association based on a less than 10% change in
the effect estimates after adjustment for MVL (%ln(CoRR)=6.7%)
and because MVL was not associated with CCR5 expression
(b=0.02, 95% CI=20.35, 0.39). Although the estimates of the
association between CCR5 expression and each transmission time
point were not very precise, a similar increased risk of transmission
was observed for higher expression of CCR5 at all time points
(Table 3). No significant association between the heparan sulfate
genes and HIV MTCT was observed (data not shown).
CCR5 Variants and HIV MTCT
The findings of Pedersen et al. [44] were replicated in this subset
of the original cohort from Malawi, with regards to the direction of
association between each CCR5 SNP and HIV MTCT. One
exception was the association between CCR5-1835T and the risk
of HIV MTCT, which varied slightly in direction compared to
previous findings (OR=1.06 vs. RR=0.84) [44]. Some findings
also had variable statistical significance which may be a reflection
of sample size (Table S3).
Regulation of CCR5 Expression
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This study evaluated the regulation of CCR5 expression in the
placenta by genetic and environmental factors involved in the risk
of HIV MTCT. Infant CCR5 promoter polymorphisms -2132T
and -2554T were associated with lower expression of CCR5 in the
placenta, as was the infant haplotype D, which is tagged by these
alleles. Infant haplotype A was associated with significantly higher
Table 1. Frequencies and mean CCR5 expression by CCR5 SNP/haplotype category.
SNP/Haplotype
Genotype
/# Copies£ N
Log % Change by Genotype
N, Mean (Range) b (95% CI){ p OR (95% CI) { p
CCR2-64VRIV V
VI
II
142
62
10
131, 5,82 (21.61, 14.55)
57, 5.59 (0.69, 12.33)
10, 5.36 (2.30, 7.15)
20.27 (20.87, 0.32) 0.374 0.69 (0.39, 1.24) 0.213
CCR5-2733ARGA A
AG
GG
190
21
1
177, 5.74 (21.61, 14.55)
19, 5.75 (2.56, 9.33)
0, NA
0.01 (20.95, 0.97) 0.981 0.97 (0.38, 2.51) 0.957
CCR5-2554GRTG G
GT
TT
102
95
15
94, 6.09 (2.30, 14.55)
89, 5.40 (21.61, 9.91)
13, 5.52 (2.77, 9.43)
20.67 (21.23, 20.11) 0.019 0.61 (0.35, 1.08) 0.091
CCR5-2459ARGA A
AG
GG
57
113
42
53, 5.97 (21.61, 14.55)
105, 5.62 (0.69, 12.33)
38, 5.76 (2.30, 9.25)
20.32 (20.96, 0.32) 0.324 0.62 (0.33, 1.17) 0.142
CCR5-2135CRTC C
CT
TT
58
112
42
54, 6.00 (21.61, 14.55)
104, 5.62 (0.69, 12.33)
38, 5.70 (2.30, 9.25)
20.36 (20.99, 0.28) 0.269 0.59 (0.31, 1.11) 0.104
CCR5-2132CRTC C
CT
TT
127
71
14
114, 6.05 (2.30, 14.55)
68, 5.09 (21.61, 9.40)
14, 6.33 (2.77, 9.43)
20.75 (20.131, 20.18) 0.010 0.45 (0.25, 0.81) 0.007
CCR5-2086ARGA A
AG
GG
182
28
3
171, 5.70 (21.61, 14.55)
25, 6.15 (3.49, 9.91)
1, 3.37 (3.37, 3.37)
0.34 (20.49, 1.18) 0.418 1.86 (0.80, 4.33) 0.149
CCR5-1835CRTC C
CT
TT
130
71
12
120, 5.93 (21.61, 14.55)
65, 5.41 (0.69, 12.32)
12, 5.67 (2.30, 9.25)
20.48 (21.05, 0.099) 0.104 0.59 (0.33, 1.05) 0.074
SNP/Haplotype
Genotype
/# Copies N
Log % Change by Genotype
N, Mean (Range) b (95% CI){ p OR (95% CI) { p
Haplotype A (VAGGTCAC) 0
1
2
120
81
11
110, 5.48 (0.69, 9.42)
75, 5.82 (21.60, 12.33)
11, 7.80 (5.46, 14.55)
0.59 (0.02, 1.16) 0.042 2.08 (1.17, 3.70) 0.012
Haplotype B (VATGTCAC) 0
1
2
205
7
0
189, 5.74 (21.61, 14.55)
7, 5.85 (3.14, 8.76)
0, NA
0.12 (21.42, 1.65) 0.880 1.47 (0.32, 6.73) 0.622
Haplotype C (VATGTCGC) 0
1
2
181
28
3
170, 5.69 (21.60, 14.55)
25, 6.15 (3.50, 9.91)
1, 3.37 (3.37, 3.37)
0.35 (20.49, 1.19) 0.411 1.89 (0.81, 4.40) 0.141
Haplotype D (VATGTTAC) 0
1
2
138
64
10
125, 6.09 (2.30, 14.55)
61, 5.01 (21.61, 9.40)
10, 5.88 (2.77, 9.43)
20.96 (21.54, 20.38) 0.001 0.36 (0.20, 0.67) 0.001
Haplotype E (VAGACCAC) 0
1
2
141
65
6
131, 5.66 (21.61, 14.55)
59, 5.97 (1.95, 9.76)
6, 5.24 (4.38, 7.48)
0.25 (20.36, 0.85) 0.420 1.08 (0.60, 1.96) 0.802
Haplotype F1 (VAGACCAT) 0
1
2
200
11
1
185, 5.77 (21.61, 14.55)
10, 5.17 (3.14, 9.25)
1, 5.22 (5.22, 5.22)
20.60 (21.83, 0.64) 0.342 0.60 (0.17, 2.13) 0.432
Haplotype F2 (IAGACCAT) 0
1
2
140
62
10
129, 5.83 (21.61, 14.55)
57, 5.60 (0.69, 12.33)
10, 5.36 (2.30, 7.15)
20.28 (20.88, 0.32) 0.358 0.69 (0.38, 1.24) 0.214
Haplotype G1 (VGGACCAC) 0
1
2
190
21
1
177, 5.74 (21.61, 14.55)
19, 5.75 (2.56, 9.33)
0, NA
0.01 (20.95, 0.97) 0.981 0.97 (0.38 2.51) 0.957
{Linear regression for the association between CCR5 expression and CCR5 SNP/haplotype: Continuous outcome of placental expression. b: Beta coefficient, 95% CI: 95%
Confidence Interval for the Beta, p: p-value.
{Logistic regression for the association between CCR5 expression and CCR5 SNP/haplotype: Dichotomous outcome of high vs. low placental expression of CCR5
dichotomized at the median value. OR: Odds Ratio, 95% CI: 95% Confidence Interval for the Odds Ratio.
£ # Copies: Number of copies of haplotype: 0, 1, or 2 copies possible per subject. SNPs and haplotypes categorized as having one or more copies of the variant allele or
haplotype compared to zero copies.
doi:10.1371/journal.pone.0009212.t001
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D in that it contains the wild type alleles, -2132C and -2554G
(Table S1) [44]. These findings provide in vivo evidence for CCR5-
2554 GRT and CCR5 -2132CRT related down regulation of
CCR5 expression in the placenta.
We expected the SNPs associated with lower CCR5 expression
to also be associated with a lower risk of HIV MTCT, and for
SNPs associated with higher CCR5 expression to be associated
with a higher risk of HIV MTCT. Referring to the association
between infant CCR2/CCR5 SNPs and HIV MTCT previously
described [44] and based on our replicate analyses, we found that
this was not always the case. Notably, CCR5 -2733G was
associated with higher CCR5 expression compared to a lower risk
of HIV MTCT, although the association with expression was not
statistically significant (Table S3). CCR5 SNPs -2554T, -2132T,
and -2086G also showed discrepant associations for CCR5
expression and HIV MTCT, with variable statistical significance.
The only discrepant finding that was statistically significant for
both associations was observed for the D haplotype, which was
associated with lower CCR5 expression but a higher risk of HIV
MTCT (Table S3). Haplotype D varies from all other haplotypes
with regards to the -2132T allele, which displayed similar results
(Table S3). It is possible that these discrepancies reflect smaller
sample sizes or the fact that we are comparing infant genotypes/
haplotypes with a combined measurement of infant and maternal
placental gene expression. More expensive techniques were
required to separate mother and infant tissue and we were unable
to pursue this in our study. Despite this limitation, the SNP/
haplotype associations suggest that predictors of CCR5 expression
do not directly correlate to the prediction of HIV MTCT and that
these outcomes should be considered independently.
The discrepant SNP/haplotype associations with CCR5 expres-
sion and HIV MTCT were partnered with the finding that CCR5
placental expression was not associated with HIV MTCT. To
obtain the best power, this association was first evaluated by using
the cumulative transmission status of the infant (occurring at birth,
6 weeks, or 12 weeks postpartum), and showed no significant
association. Because placenta samples were obtained at delivery,
the measured CCR5 expression was viewed to be most represen-
tative of the expression occurring during labor and delivery and
thus, most relevant to the risk of IP transmission. For both
cumulative and IP transmission, although the direction of effect
was consistent with previous findings [17], where an increase in
CCR5 expression contributed to an increase in the risk of HIV
MTCT, the association was not statistically significant. It is likely
that other factors played a stronger role in predicting HIV MTCT
in this study population.
Disease severity appeared to be an important regulator of
placental expression of CCR5. Among HIV infected mothers,
higher maternal HIV viral load was significantly associated with
higher CCR5 placental expression. Thus, the presence of HIV
infection alone may not make as great of an impact on CCR5
expression as does the severity of HIV disease or viral burden
experienced by the individual.
Figure 1. Pattern of association between placental expression of heparan sulfate genes and CCR5. Scatter Plots (left) and Predicted
Linear Plots (right).
doi:10.1371/journal.pone.0009212.g001
Table 2. Linear regression for the associations between gene
expression variables.
Comparison{ b (95% CI) p
HS3ST3A1 vs. CCR5 expression (N=197) 0.27 (0.18, 0.35) ,0.0001
HS3ST3B1 vs. CCR5 expression (N=180) 0.11 (0.06, 0.18) ,0.0001
{Continuous placental gene expression variables compared via linear
regression; b: Beta coefficient; 95% CI: 95% Confidence Interval for the Beta;
p: p-value.
doi:10.1371/journal.pone.0009212.t002
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significant predictor of CCR5 expression. We limited this analysis to
only HIV positive mothers and found that maternal malaria did
increase CCR5 expression in the placenta but that it was not
statistically significant (data not shown). Thus, we could not make
any broad conclusions from the analyses with malaria. Further-
more, MVL and maternal malaria did not confound or act as effect
measure modifiers in the associations between CCR5 expression
and HIV MTCT, suggesting that accounting for a key co-infection
or severity of HIV infection did not explain the lack of a significant
association between CCR5 expression and HIV MTCT.
One of the most important findings from this study was the
revelation of a possible interaction between CCR5 and heparan
sulfate at the genetic level. Up-regulation of CCR5 expression in
the placenta was observed at higher expression levels of two genes
involved in the biosynthesis of 3-O-sulfated heparan sulfate,
HS3ST3A1 and HS3ST3B1. These findings were statistically
significant and to our knowledge, are novel in vivo findings. It is
possible that each heparan sulfate gene interacts with CCR5 in the
placenta, causing up-regulation, or that the genes share transcrip-
tion regulatory regions or factors. As previously noted, heparan
sulfate has been shown to interact with chemokines which bind to
CCR5, such as RANTES, but has not been evaluated for any
interaction with CCR5 or related factors at the genetic level. Our
findings press the importance of additional research on heparan
sulfate and CCR5–related factors that may individually or
cooperatively contribute to viral infection in human populations.
Overall, this study demonstrated the complexity of predicting
HIV MTCT in human populations and offers new insights into
regulatory factors of CCR5 expression in the placenta. Additional
epidemiological investigations are warranted in order to more
clearly elucidate how CCR5 and heparan sulfate genes may
interact in vivo and whether combined genetic and environmental
factors contribute to the risk of HIV MTCT in other populations.
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